Navigation Links
Breast Cancer Vaccine Works Against Deadlier Form of Disease
Date:4/13/2008

It reduced mortality among women with HER2 malignancies, study shows

SUNDAY, April 13 (HealthDay News) -- A breast cancer vaccine significantly reduced the risk of recurrence for patients who have a high expression of the protein HER2-neu.

This type of breast cancer, representing about one-quarter of all cases, tends to be deadlier than other forms of the disease. In this group, the vaccine reduced mortality by 50 percent.

Even better, however, the vaccine lowered mortality by 100 percent in women with breast cancer and low or intermediate expression of HER2/neu. Currently, these women have no therapies other than conventional cancer treatments such as surgery and chemo.

"We now have something we think works in the majority of women with breast cancer who are currently underserved," said Dr. George Peoples, senior author of the study, which is expected to be presented at the American Association for Cancer Research annual meeting, in San Diego. "It's also very, very well-tolerated, like a flu shot."

Peoples is chief of surgical oncology at Brooke Army Medical Center in San Antonio and director of the Cancer Vaccine Development Program at the U.S. Military Cancer Institute.

According to study lead author, Dr. Linda Benavides, a resident in general surgery at Brooke Army Medical Center, the biotech firm, Apthera, has licensed the vaccine, named it NeuVax, and is currently planning phase 3 clinical trials.

But there's still no guarantee the vaccine will reach the market.

"It is a very exciting area of research, but it's very exploratory and not ready for prime time," said Dr. Minetta Liu, a translational researcher/breast oncologist at Georgetown's Lombardi Comprehensive Cancer Center.

Other cancer vaccines have been tested, mostly to treat tumors that have already spread, with little success.

"We've been studying vaccines in the setting of metastatic cancer, but the immune system has already been effective, and the cat's out of the bag already," Liu said. "Many of us believe the time to get rid of them is as they're developing. It's just so hard to study it in that setting."

This vaccine (also known as E75), which stimulates the immune system to recognize the cancer as foreign, aims to prevent a recurrence in women who have already had one round of cancer. It is the furthest along of all the cancer vaccines.

This trial involved 165 breast cancer patients with HER2/neu tumors and lymph node involvement; 94 were vaccinated (initial shot plus boosters) and 71 served as controls.

Immunity was raised in all women who received the vaccine, but the biggest benefit was seen in those women with low and intermediate expression of HER2/neu or those who are not eligible for Herceptin, the drug currently used to treat this type of cancer.

After a follow-up of about 30 months, recurrence rates were similar between high overexpressors in both the vaccine and control groups (18.2. percent and 13.8 percent, respectively). But, there was a greater than 50 percent reduction in mortality rates.

In those with low or intermediate expression of the protein, results were more startling. Less than 11 percent of low HER2/neu expressors had a recurrence, versus 18.2 percent in the control group. The mortality rate in the vaccine group was zero, compared with 38 percent in the control group.

More information

Visit the National Cancer Institute for more on breast cancer.



SOURCES: Linda Benavides, M.D., resident, general surgery, Brooke Army Medical Center, San Antonio; George Peoples, M.D., chief, surgical oncology, Brooke Army Medical Center, San Antonio, and director, Cancer Vaccine Development Program, U.S. Military Cancer Institute; Minetta Liu, M.D., translational researcher/breast oncologist, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, D.C.; April 13, 2008, presentation, American Association of Cancer Research annual meeting, San Diego


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Susan G. Komen for the Cure(R) Calls on Policymakers to Address Unfairness in Breast Cancer Incidence and Mortality
2. Doctor-Patient Talks Affect Use of Breast Reconstruction Surgery
3. Radiation beneficial for older breast cancer patients
4. Mammography plus sonography can help rule out breast cancer in patients with palpable lesions
5. Newly diagnosed breast cancer patients benefit from use of USFNA of lymph nodes
6. MRI changes breast cancer treatment choice; increases time to treatment
7. A diagnosis of triple-negative breast cancer doesnt always mean cancer spread
8. MRI best for looking at breast cancer and more
9. Breast Surgery Today ... Out to Dinner Tonight
10. Massachusetts Affiliate of Susan G. Komen for the Cure(R) to Challenge States Leaders to Strengthen Breast Cancer Services
11. Massachusetts Affiliate of Susan G. Komen for the Cure to Spotlight Gaps in Breast Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Breast Cancer Vaccine Works Against Deadlier Form of Disease
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate ... in Latin America . ... ... ... ...
(Date:6/23/2016)... 23, 2016 The vast majority of dialysis ... facility.  Treatments are usually 3 times a week, with ... including travel time, equipment preparation and wait time.  This ... grueling for patients who are elderly and frail.  Many ... and rehabilitation centers for some duration of time. ...
(Date:6/23/2016)... June 23, 2016 The Biotechnology ... continues to present great opportunities to investors. Stock-Callers.com assesses ... Intrexon Corp. (NYSE: XON ), Vertex Pharmaceuticals ... (NASDAQ: ARNA ), and Regeneron Pharmaceuticals Inc. ... stocks and receive your complimentary trade alerts at: ...
Breaking Medicine Technology: